In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Royce & Associates LP | 1.66M | $9.0M | 3.09% | +592.2K | 2026-06-30 |
| Vanguard Capital Management LLC | 1.61M | $9.0M | 3.01% | +1.17M | 2026-06-30 |
| Roubaix Capital, LLC | 1.58M | $8.0M | 2.94% | -303.0K | 2026-06-30 |
| BlackRock, Inc. | 879.8K | $4.0M | 1.64% | +163.0K | 2026-06-30 |
| UBS Group AG | 632.0K | $3.0M | 1.18% | +306.8K | 2026-06-30 |
| Conestoga Capital Advisors, LLC | 314.6K | $1.0M | 0.59% | -2.5K | 2026-06-30 |
| Geode Capital Management, LLC | 311.8K | $1.0M | 0.58% | +3.9K | 2026-06-30 |
| Bank of America Corp | 255.8K | $1.0M | 0.48% | +27.5K | 2026-06-30 |
| Goldman Sachs Group Inc | 172.0K | -- | 0.32% | +53.6K | 2026-06-30 |
| State Street Corp | 164.9K | -- | 0.31% | +9.8K | 2026-06-30 |
